Aktuellt
SENASTE
With lead asset FG001 now being tested in evening dosing, we are approaching the end of the phase 1 portion of the trial and an important de-risking event in our valuation framework. Until now, there have been no safety signals to our knowledge, boding well for the final phase 1 topline. Following the directed share issue, we take our valuation range to SEK 108-140 (114-150).
LÄS MER
